IRVINE, Calif.--(BUSINESS WIRE)--Dec. 16, 2005--Allergan, Inc. (NYSE:AGN) announced today that it has filed a motion with the United States District Court for the Northern District of California, San Francisco Division, requesting a temporary restraining order and preliminary injunction prohibiting the sale of a proposed generic version of Allergan's non-steroidal anti-inflammatory drug ACULAR(R) (ketorolac tromethamine ophthalmic solution) 0.5% while the court conducts further proceedings in a patent infringement lawsuit brought by Allergan and Syntex (U.S.A.) LLC against Apotex, Inc., Apotex Corp., and Novex Pharma Inc. (the "Apotex Defendants").
